USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
'Hunted For His Identity': West Bengal CM Mamata Banerjee Slams Xenophobia After Bengali Worker's Murder In Pune
'Can An Impartial Investigation Even Take Place?' Sanjay Raut On Rohit Pawar Expressing Doubts Over Ajit Dada's Death In Plane Crash
Suryakumar Yadav, Ishan Kishan, Arshdeep Singh & Other Team India Players Go Gaga Over Nora Fatehi's Dance During ICC T20 WC Opening Ceremony; Video
Government To Sell BHEL Stake Via OFS For Retail Investors, Shares Offered At ₹254 Floor Price With Discount Opportunity
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
